2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P5174
    MitTx ≥98.0%
    MitTx is a complex formed by MitTx-α and MitTx-β. MitTx is an ASIC1 channel activator with EC50 values of 9.4 and 23 nM for ASIC1a and ASIC1b isoforms, respectively. MitTx is highly selective for ASIC1 isoforms at neutral pH. Under acidic conditions, MitTx greatly enhances proton-evoked ASIC2a channel activation.
    MitTx
  • HY-P5883
    TAT-M2NX 2126166-03-6 99.55%
    TAT-M2NX (tatM2NX) is a selective inhibitor targeting human TRPM2 channels and exerts inhibitory effects on ischemic stroke. TAT-M2NX reduces H2O2-induced calcium influx via TRPM2 channels. After traumatic brain injury in mice, TAT-M2NX preserves hippocampal long-term potentiation, improves memory function, and reduces infarct volume after middle cerebral artery occlusion, but it shows no effect on female mice. TAT-M2NX can be used in studies related to traumatic brain injury and ischemic stroke.
    TAT-M2NX
  • HY-100046
    Nordoxepin hydrochloride 2887-91-4 99.94%
    Nordoxepin hydrochloride is the major metabolite of Doxepin. Doxepin is a tricyclic antidepressant that is widely prescribed for the research of mild depression.
    Nordoxepin hydrochloride
  • HY-100801
    L-threo-3-Hydroxyaspartic acid 7298-99-9 98.80%
    L-threo-3-Hydroxyaspartic acid is a potent EAAT inhibitor with Kis of 11, 19 and 14 μM for EAAT1, EAAT2 and EAAT3, respectively in HEK293 cell lines.
    L-threo-3-Hydroxyaspartic acid
  • HY-100812
    2-Hydroxysaclofen 117354-64-0 98.0%
    2-Hydroxysaclofen is a potent γ-amino-butyric-acid-B (GABAB) receptor antagonist. 2-Hydroxysaclofen can abolish nicotine-induced hypolocomotor effects and increases the antinociceptive effects. 2-Hydroxysaclofen can stimulate luteinizing hormone (LH) secretion in female rats.
    2-Hydroxysaclofen
  • HY-100911
    W-5 hydrochloride 61714-25-8 99.93%
    W-5 hydrochloride is a calmodulin antagonist. W-5 hydrochloride inhibits phosphodiesterase activation with an IC50 value of 240 µM. W-5 hydrochloride can be used as a negative control for W-7 (HY-100912).
    W-5 hydrochloride
  • HY-101173
    Imetit dihydrobromide 32385-58-3 98.16%
    Imetit dihydrobromide (VUF 8325 dihydrobromide) is a high affinity and potent agonist of histamine H3 and H4 receptors, with Ki values of 0.3 and 2.7 nM, respectively. Imetit mimics histamine effect in triggering a shape change in eosinophils (EC50=25 nM).
    Imetit dihydrobromide
  • HY-101175
    3-Bromo-7-nitroindazole 74209-34-0 99.78%
    3-Bromo-7-nitroindazole is a potent and selective inhibitor of neuronal nitric oxide synthase (nNOS). 3-Bromo-7-nitroindazole affects the intercellular messenger nitric oxide (NO) synthesis throughout the body and brain. 3-Bromo-7-nitroindazole can be used for the researches of metabolic and neurological disease, such as diabetes, stroke and depression.
    3-Bromo-7-nitroindazole
  • HY-101347
    Chlorisondamine diiodide 96750-66-2 ≥98.0%
    Chlorisondamine (diiodide) is a potent nicotinic acetylcholine receptor (nAChR) antagonist and a ganglion blocker. Chlorisondamine antagonizes some of nicotine's central actions in a potent, long-lasting and pharmacologically selective way.
    Chlorisondamine diiodide
  • HY-101534
    GSK1059865 1191044-58-2 99.68%
    GSK1059865 is a potent orexin 1 receptor antagonist.
    GSK1059865
  • HY-101839
    ML381 1623481-80-0 99.87%
    ML381 (VU0488130) is a highly selective, central nervous system penetrant mAChR M5 orthogonal antagonist (IC50 = 450 nM; Ki = 340 nM). ML381 is unstable in rat plasma and can be mainly used as a molecular probe for in vitro and electrophysiological studies.
    ML381
  • HY-103162
    ANR94 634924-89-3 98.91%
    ANR94 is a potent and selective adenosine A2A receptor (AA2AR) antagonist with an Ki of 46 nM for hAA2AR. ANR94 has the potential for the research of Parkinson's disease.
    ANR94
  • HY-103180
    2'-MeCCPA 205171-12-6 99.80%
    2'-MeCCPA is a potent and selective A1 adenosine receptors (A1AR) agonist. 2'-MeCCPA efficiently inhibits cAMP modulation in both direct pathway medium spiny neurons (dMSNs) and indirect pathway medium spiny neurons (iMSNs).
    2'-MeCCPA
  • HY-103318
    PD173212 217171-01-2 98.88%
    PD173212 is a selective N-type voltage sensitive calcium channel (VSCC) blocker, with an IC50 of 36 nM in IMR-32 assays.
    PD173212
  • HY-103345
    2-MPPA 254737-29-6 98.0%
    2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC50 of 90 nM.
    2-MPPA
  • HY-103374
    Phenserine 101246-66-6 ≥98.0%
    Phenserine ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine (HY-N6608) and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ) formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease.
    Phenserine
  • HY-103520
    DS2 374084-31-8 99.94%
    DS2 is a selective positive allosteric modulator of δ-GABAA receptor. DS2 selectively potentiates GABA responses mediated by α4β3δ receptor. DS2 does not enhance activity at α4β3γ2 and α1β3γ2 receptors. DS2 relieves pain and has the potential for sleep disorders research.
    DS2
  • HY-105005
    Crisdesalazine 927685-43-6 98.92%
    Crisdesalazine (AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. Crisdesalazine acts as a potent free radical scavenger that directly neutralizes reactive oxygen species (ROS) including hydrogen peroxide, exerting neuroprotective effects against apoptosis and axonal damage. Crisdesalazine inhibits PGE2 production, mediates inflammatory responses, and promotes the conversion of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. Crisdesalazine is applicable to neuroprotection research in multiple sclerosis and spinal cord injury.
    Crisdesalazine
  • HY-105445
    CP-113818 135025-12-6 99.70%
    CP-113818 is a potent cholesterol acyltransferase (ACAT) inhibitor. CP-113818 can be used for the research of Alzheimer's disease.
    CP-113818
  • HY-107319
    Almitrine mesylate 29608-49-9 98.88%
    Almitrine mesylate, a peripheral chemoreceptor agonist, inhibits selectively the Ca2+-dependent K+ channel.
    Almitrine mesylate
Cat. No. Product Name / Synonyms Application Reactivity